A neoantigen peptide mutated in tumor cells can be presented at the cell surface of MHC-I class molecules, and the T-cell receptor (TCR) on the surface of CD8+ T cells recognizes and binds the neoantigen peptide–MHC complex, thereby exerting an antitumor immune effect by killing tumor cells directly [127]. Here, CD8A is linked to neoplasm.